Overview

MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)

Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.
Phase:
Phase 4
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Abbott
Boehringer Ingelheim
Treatments:
Lamivudine
Lopinavir
Nevirapine
Ritonavir
Zidovudine